Lung Cancer Clinical Trial
Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining imatinib mesylate with chemotherapy may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining imatinib mesylate with irinotecan and cisplatin in treating patients who have extensive-stage small cell lung cancer
Full Description
OBJECTIVES:
Determine the maximum tolerated dose of imatinib mesylate when administered with irinotecan and cisplatin in patients with extensive stage small cell lung cancer.
Determine the effect of imatinib mesylate on irinotecan metabolism by the cytochrome p450 system in these patients.
Determine the response rate, time to progression, and survival of patients treated with this regimen.
OUTLINE: This is a dose-escalation study of imatinib mesylate.
Patients receive irinotecan IV over 30 minutes on days 1, 8, and 15 and cisplatin IV over 60 minutes on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral imatinib mesylate once or twice daily beginning on day 22 of course 1 and continuing until disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: Approximately 18 patients will be accrued for this study within 12-18 months.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed small cell lung cancer
Extensive stage disease
Measurable or evaluable indicator lesion
No symptomatic or uncontrolled brain or leptomeningeal involvement
PATIENT CHARACTERISTICS:
Age
18 and over
Performance status
Karnofsky 70-100%
Life expectancy
Not specified
Hematopoietic
WBC at least 4,000/mm3
Platelet count at least 160,000/mm3
Hemoglobin at least 10 g/dL
Hepatic
Bilirubin no greater than 1 mg/dL
AST no greater than 2.5 times upper limit of normal (ULN)
Alkaline phosphatase no greater than 5 times ULN
Renal
Creatinine less than 1.5 mg/dL OR
Creatinine clearance at least 50 mL/min
Cardiovascular
No symptomatic congestive heart failure
No unstable angina pectoris
No uncontrolled cardiac arrhythmia
Other
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective barrier contraception during and for 3 months after study
No other active cancer except previously treated carcinoma in situ, non -melanoma skin cancer, or stage I prostate cancer
No ongoing or active infection
No psychiatric illness or social situation that would preclude study
No other concurrent uncontrolled illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
Not specified
Chemotherapy
No prior chemotherapy except for non-cancer conditions (e.g., low-dose methotrexate for rheumatoid arthritis)
Endocrine therapy
Not specified
Radiotherapy
At least 2 weeks since prior radiotherapy to major bone marrow-containing areas
Surgery
Not specified
Other
No concurrent warfarin for therapeutic anticoagulation
Low-molecular weight heparin or heparin allowed
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10021, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.